These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clozapine-associated severe eosinophilia following lithium rebound neutropenia: A case report.
    Author: Kikuchi K, Yasui-Furukori N, Yokoyama S, Hasegawa C, Kokubun A, Katsukura S, Shimizu T, Shimoda K.
    Journal: Neuropsychopharmacol Rep; 2020 Dec; 40(4):388-391. PubMed ID: 32951324.
    Abstract:
    BACKGROUND: Clozapine use is complicated by an increased risk of hematological adverse effects such as neutropenia and, rarely, eosinophilia. CASE PRESENTATION: We present the case of a 48-year-old man with treatment-resistant schizophrenia. On day 12 after clozapine initiation, he had a cough with a temperature of 39.8°C. On day 16, his leukocyte count had increased to 9320 cells/mm3 (neutrophils 7550 cells/mm3 and eosinophils 680 cells/mm3 ). We discontinued lithium because of neutrophilia and damage to renal function on day 20. His eosinophil count increased until day 29, reaching 6750 cells/mm3 . We suspected a drug-induced reaction and discontinued clozapine on day 30. His eosinophil count gradually decreased, reaching the normal range by day 40. However, his leukocyte and neutrophil counts also gradually decreased to below than the normal range by day 40. His leukocytes and neutrophil counts had recovered by day 55. CONCLUSION: We concluded that this patient had clozapine-associated severe eosinophilia following lithium rebound neutropenia.
    [Abstract] [Full Text] [Related] [New Search]